Timing of coronavirus disease 2019 (COVID-19) vaccination and effects on menstrual cycle changes
File(s)timing_of_coronavirus_disease_2019__covid_19_.18.pdf (444.73 KB)
Published version
Author(s)
Type
Journal Article
Abstract
OBJECTIVE:
To assess whether menstrual cycle timing (follicular or luteal phase) of coronavirus disease 2019 (COVID-19) vaccine administration is associated with cycle length changes.
METHODS:
We used prospectively collected (2021–2022) menstrual cycle tracking data from 19,497 reproductive-aged users of the application “Natural Cycles.” We identified whether vaccine was delivered in the follicular or luteal phase and also included an unvaccinated control group. Our primary outcome was the adjusted within-individual change in cycle length (in days) from the average of the three menstrual cycles before the first vaccination cycle (individuals in the unvaccinated control group were assigned a notional vaccine date). We also assessed cycle length changes in the second vaccination cycle and whether a clinically significant change in cycle length (8 days or more) occurred in either cycle.
RESULTS:
Most individuals were younger than age 35 years (80.1%) and from North America (28.6%), continental Europe (33.5%), or the United Kingdom (31.7%). In the vaccinated group, the majority received an mRNA vaccine (63.8% of the full sample). Individuals vaccinated in the follicular phase experienced an average 1-day longer adjusted cycle length with a first or second dose of COVID-19 vaccine compared with their prevaccination average (first dose: 1.00 day [98.75% CI, 0.88–1.13], second dose: 1.11 days [98.75% CI, 0.93–1.29]); those vaccinated in the luteal phase and those in the unvaccinated control group experienced no change in cycle length (respectively, first dose: −0.09 days [98.75% CI, −0.26 to 0.07], second dose: 0.06 days [98.75% CI, −0.16 to 0.29], unvaccinated notional first dose: 0.08 days [98.75% CI, −0.10 to 0.27], second dose: 0.17 days [98.75% CI, −0.04 to 0.38]). Those vaccinated during the follicular phase were also more likely to experience a clinically significant change in cycle length (8 days or more; first dose: 6.8%) than those vaccinated in the luteal phase or unvaccinated (3.3% and 5.0%, respectively; P<.001).
CONCLUSION:
COVID-19 vaccine–related cycle length increases are associated with receipt of vaccination in the first half of the menstrual cycle (follicular phase).
To assess whether menstrual cycle timing (follicular or luteal phase) of coronavirus disease 2019 (COVID-19) vaccine administration is associated with cycle length changes.
METHODS:
We used prospectively collected (2021–2022) menstrual cycle tracking data from 19,497 reproductive-aged users of the application “Natural Cycles.” We identified whether vaccine was delivered in the follicular or luteal phase and also included an unvaccinated control group. Our primary outcome was the adjusted within-individual change in cycle length (in days) from the average of the three menstrual cycles before the first vaccination cycle (individuals in the unvaccinated control group were assigned a notional vaccine date). We also assessed cycle length changes in the second vaccination cycle and whether a clinically significant change in cycle length (8 days or more) occurred in either cycle.
RESULTS:
Most individuals were younger than age 35 years (80.1%) and from North America (28.6%), continental Europe (33.5%), or the United Kingdom (31.7%). In the vaccinated group, the majority received an mRNA vaccine (63.8% of the full sample). Individuals vaccinated in the follicular phase experienced an average 1-day longer adjusted cycle length with a first or second dose of COVID-19 vaccine compared with their prevaccination average (first dose: 1.00 day [98.75% CI, 0.88–1.13], second dose: 1.11 days [98.75% CI, 0.93–1.29]); those vaccinated in the luteal phase and those in the unvaccinated control group experienced no change in cycle length (respectively, first dose: −0.09 days [98.75% CI, −0.26 to 0.07], second dose: 0.06 days [98.75% CI, −0.16 to 0.29], unvaccinated notional first dose: 0.08 days [98.75% CI, −0.10 to 0.27], second dose: 0.17 days [98.75% CI, −0.04 to 0.38]). Those vaccinated during the follicular phase were also more likely to experience a clinically significant change in cycle length (8 days or more; first dose: 6.8%) than those vaccinated in the luteal phase or unvaccinated (3.3% and 5.0%, respectively; P<.001).
CONCLUSION:
COVID-19 vaccine–related cycle length increases are associated with receipt of vaccination in the first half of the menstrual cycle (follicular phase).
Date Issued
2024-04
Date Acceptance
2024-02-08
Citation
Obstetrics and Gynecology, 2024, 143 (4), pp.585-594
ISSN
0029-7844
Publisher
Lippincott, Williams & Wilkins
Start Page
585
End Page
594
Journal / Book Title
Obstetrics and Gynecology
Volume
143
Issue
4
Copyright Statement
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. This
is an open access article distributed under the Creative Commons Attribution
License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
is an open access article distributed under the Creative Commons Attribution
License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
License URL
Identifier
http://dx.doi.org/10.1097/aog.0000000000005550
Publication Status
Published
Date Publish Online
2024-02-27